Jefferies Group’s Theriva Biologics TOVX Stock Holding History

Jefferies Group’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-3	Closed	-$56K	–	2444
2016 Q1	$56K	Buy	+3	New	+$45.1K	﹤0.01%	2029

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jefferies Group's TOVX Position: Q2 2016 in Review

Jefferies Group sold out of Theriva Biologics (TOVX) in Q2 2016, closing a stake of 3 shares — an estimated $56K sold.

Jefferies Group first reported a position in TOVX in Q1 2016 and held it in 1 quarter. The position peaked at $56K in Q1 2016. 61 funds tracked by Wall St. Rank hold TOVX as of Q2 2016.

Jefferies Group reported no remaining Theriva Biologics position as of Q2 2016 after selling out during the quarter.
Jefferies Group sold 3 Theriva Biologics shares in Q2 2016, an estimated $56K.
Jefferies Group first reported a position in Theriva Biologics in Q1 2016 and held it in 1 quarter.
Jefferies Group's Theriva Biologics position peaked at $56K in Q1 2016.
61 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2016.

Based on Jefferies Group's 13F filing for Q2 2016, filed 12 Aug 2016.